TY - JOUR
T1 - Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment
AU - Shafat, Itay
AU - Barak, Ayelet Ben
AU - Postovsky, Sergey
AU - Elhasid, Ronit
AU - Ilan, Neta
AU - Vlodavsky, Israel
AU - Ben Arush, Miriam Weyl
N1 - Funding Information:
Abbreviations: CR, complete remission; ECM, extracellular matrix; ES, Ewing’s sarcoma; HD, Hodgkin’s disease; HS, heparan sulfate; TP, tumor progression; VGPR, very good partial remission Address all correspondence to: Israel Vlodavsky, Cancer and Vascular Biology Research Center, Rappaport Faculty of Medicine, Technion, P. O. Box 9649, Haifa 31096, Israel. E-mail: [email protected] 1This work was supported by grants from the Israel Science Foundation (grant 549/06); National Cancer Institute, National Institutes of Health (grant ROI-CA106456); the Israel Cancer Research Fund; and the Cooperation Program in Cancer Research of the Deutsches Krebsforschungszentrum and Israel’s Ministry of Sciences and Technology. Received 2 August 2007; Revised 6 September 2007; Accepted 7 September 2007.
PY - 2007/11
Y1 - 2007/11
N2 - Heparanase is an endoglycosidase that specifically cleaves heparan sulfate (HS) side chains of heparan sulfate proteoglycans, the major proteoglycan in the extracellular matrix (ECM) and cell surfaces. Heparanase upregulation was documented in an increasing number of primary human tumors, correlating with reduced postoperative survival rate and enhanced tumor angiogenesis. The purpose of the current study was to determine heparanase levels in blood samples collected from pediatric cancer patients using an ELISA method. Heparanase levels were elevated four-fold in the plasma of cancer patients compared with healthy controls (664 ± 143 vs 163 ± 18 pg/ml, respectively). Evaluating plasma samples following anticancer therapy revealed reduced heparanase levels (664 ± 143 vs 429 ± 82 pg/ml), differences that are statistically highly significant (P = .0048). Of the 55 patients with complete remission (CR) or very good partial remission (VGPR) at restaging, 41 (74.5%) had lower heparanase amounts, whereas 14 patients (25.5%) had similar or higher amounts of plasma heparanase. All nine patients with stable or advancing disease had similar or elevated levels of heparanase on restaging. The results show that heparanase levels are elevated in the plasma of pediatric cancer patients and closely correlate with treatment responsiveness, indicating that heparanase levels can be used to diagnose and monitor patient's response to anticancer treatment.
AB - Heparanase is an endoglycosidase that specifically cleaves heparan sulfate (HS) side chains of heparan sulfate proteoglycans, the major proteoglycan in the extracellular matrix (ECM) and cell surfaces. Heparanase upregulation was documented in an increasing number of primary human tumors, correlating with reduced postoperative survival rate and enhanced tumor angiogenesis. The purpose of the current study was to determine heparanase levels in blood samples collected from pediatric cancer patients using an ELISA method. Heparanase levels were elevated four-fold in the plasma of cancer patients compared with healthy controls (664 ± 143 vs 163 ± 18 pg/ml, respectively). Evaluating plasma samples following anticancer therapy revealed reduced heparanase levels (664 ± 143 vs 429 ± 82 pg/ml), differences that are statistically highly significant (P = .0048). Of the 55 patients with complete remission (CR) or very good partial remission (VGPR) at restaging, 41 (74.5%) had lower heparanase amounts, whereas 14 patients (25.5%) had similar or higher amounts of plasma heparanase. All nine patients with stable or advancing disease had similar or elevated levels of heparanase on restaging. The results show that heparanase levels are elevated in the plasma of pediatric cancer patients and closely correlate with treatment responsiveness, indicating that heparanase levels can be used to diagnose and monitor patient's response to anticancer treatment.
KW - Anticancer treatment
KW - ELISA
KW - Heparanase
KW - Marker
UR - http://www.scopus.com/inward/record.url?scp=36048945359&partnerID=8YFLogxK
U2 - 10.1593/neo.07673
DO - 10.1593/neo.07673
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 18030359
AN - SCOPUS:36048945359
SN - 1522-8002
VL - 9
SP - 909
EP - 916
JO - Neoplasia
JF - Neoplasia
IS - 11
ER -